GENERAL·Financial Post·
Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough
LAVAL, Québec — Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following th…
Summary curated by Max Robotics. Original article © Financial Post.